Codexis, Inc. (CDXS)
- GlobeNewswire
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platformREDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agricu
- Simply Wall St.
Favourable Signals For Codexis: Numerous Insiders Acquired Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- Insider Monkey
Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript February 28, 2024 Codexis, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.16. CDXS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Codexis Fourth Quarter and Full […]
